<DOC>
	<DOC>NCT02045693</DOC>
	<brief_summary>The purpose of this study is to assess the effects of steady state DCV/ASV/BMS-791325 fixed dose combination (FDC) + 75mg BMS-791325 on the Pharmacokinetics (PK) of Methadone in subjects with the stable dose of Methadone and on the PK of Buprenorphine in subjects with the stable dose of Buprenorphine.</brief_summary>
	<brief_title>Drug Interaction &amp; Methadone &amp; Buprenorphine</brief_title>
	<detailed_description>IND number: 101,943 Primary purpose: Other: Phase 1 Clinical Pharmacology drug interaction study in healthy subjects</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Subject must be on stable Methadone or Buprenorphine regimens for at least 28 days prior to screening Subjects must be healthy except for history of Methadone or Buprenorphine treatment regimens Prior exposure to DCV, ASV or BMS791325 within 3 months of screening or any other investigational drug or placebo within 4 weeks of study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>